Citadel Advisors’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-22,400
| Closed | -$76K | – | 10221 |
|
|
2018
Q3 | $76K | Sell |
22,400
-28,300
| -56% | -$102K | ﹤0.01% | 8682 |
|
|
2018
Q2 | $191K | Sell |
50,700
-53,900
| -52% | -$262K | ﹤0.01% | 7923 |
|
|
2018
Q1 | $428K | Buy |
104,600
+9,600
| +10% | +$44.7K | ﹤0.01% | 6166 |
|
|
2017
Q4 | $442K | Buy |
+95,000
| New | +$523K | ﹤0.01% | 5847 |
|
|
2017
Q3 | – | Sell |
-58,000
| Closed | -$419K | – | 8379 |
|
|
2017
Q2 | $419K | Buy |
58,000
+42,700
| +279% | +$267K | ﹤0.01% | 5374 |
|
|
2017
Q1 | $94K | Sell |
15,300
-73,500
| -83% | -$403K | ﹤0.01% | 6882 |
|
|
2016
Q4 | $520K | Sell |
88,800
-29,100
| -25% | -$159K | ﹤0.01% | 4836 |
|
|
2016
Q3 | $626K | Buy |
117,900
+13,700
| +13% | +$73.9K | ﹤0.01% | 4507 |
|
|
2016
Q2 | $690K | Buy |
104,200
+15,800
| +18% | +$88.3K | ﹤0.01% | 4054 |
|
|
2016
Q1 | $413K | Sell |
88,400
-49,100
| -36% | -$196K | ﹤0.01% | 4667 |
|
|
2015
Q4 | $694K | Sell |
137,500
-12,600
| -8% | -$59.9K | ﹤0.01% | 4053 |
|
|
2015
Q3 | $528K | Buy |
150,100
+51,500
| +52% | +$345K | ﹤0.01% | 4737 |
|
|
2015
Q2 | $984K | Buy |
98,600
+34,200
| +53% | +$367K | ﹤0.01% | 3975 |
|
|
2015
Q1 | $820K | Sell |
64,400
-1,100
| -2% | -$14.1K | ﹤0.01% | 4205 |
|
|
2014
Q4 | $927K | Buy |
65,500
+10,100
| +18% | +$157K | ﹤0.01% | 3862 |
|
|
2014
Q3 | $762K | Buy |
55,400
+37,300
| +206% | +$571K | ﹤0.01% | 4063 |
|
|
2014
Q2 | $278K | Sell |
18,100
-31,500
| -64% | -$447K | ﹤0.01% | 5158 |
|
|
2014
Q1 | $845K | Buy |
49,600
+6,100
| +14% | +$92K | ﹤0.01% | 3651 |
|
|
2013
Q4 | $563K | Sell |
43,500
-27,700
| -39% | -$331K | ﹤0.01% | 3867 |
|
|
2013
Q3 | $719K | Buy |
71,200
+43,000
| +152% | +$383K | ﹤0.01% | 3430 |
|
|
2013
Q2 | $211K | Buy |
+28,200
| New | +$220K | ﹤0.01% | 4626 |
|
Citadel Advisors's KERX Position: Q4 2018 in Review
Citadel Advisors sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 44,686 shares — an estimated $152K sold.
Citadel Advisors first reported a position in KERX in Q2 2013 and held it in 21 quarters. The position peaked at $3.51M in Q1 2014. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- Citadel Advisors reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- Citadel Advisors sold 44,686 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $152K.
- Citadel Advisors first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 21 quarters.
- Citadel Advisors's Keryx Biopharmaceuticals Inc position peaked at $3.51M in Q1 2014.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on Citadel Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.